Inclusion Criteria:  Diagnosis and clinical course falling into one of the following categories:  Hodgkin lymphoma Aggressive non-Hodgkin lymphoma ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma ALK-positive anaplastic T cell lymphoma CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory. Age 12 to 75. Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal. AST 3 times or less than the upper limit of normal. Estimated GFR > 70 mL/min. Pulse oximetry of > 90% on room air EKG shows no significant arrhythmias Karnofsky or Lansky score of > 60%. Available allogeneic T cells with ≥15% expression of CD30CAR determined by flow-cytometry. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.  Exclusion Criteria:  Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks. Received CD30 antibody-based therapy within the previous 4 weeks. History of hypersensitivity reactions to murine protein-containing products. Pregnant or lactating. Tumor in a location where enlargement could cause airway obstruction. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg/day of prednisone. Active significant, uncontrolled bacterial, viral or fungal infection. Symptomatic cardiac disease (NYHA Class III or IV disease).